Raimar LÃ¶benberg

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2835058/publications.pdf

Version: 2024-02-01

158	6,447	109321	74163
papers	citations	35 h-index	75 g-index

165	165	165	6723
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Oral administration of buparvaquone nanostructured lipid carrier enables in vivo activity against Leishmania infantum. European Journal of Pharmaceutical Sciences, 2022, 169, 106097.	4.0	7
2	Investigations of the antipyretic effect and safety of Prasachandaeng, a traditional remedy from Thailand national list of essential medicines. Biomedicine and Pharmacotherapy, 2022, 147, 112673.	5.6	5
3	Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity. Cell Reports Medicine, 2022, 3, 100534.	6.5	7
4	In Vitro Evaluation of a Foamable Microemulsion Towards an Improved Topical Delivery of Diclofenac Sodium. AAPS PharmSciTech, 2022, 23, 102.	3.3	2
5	Vaping additives negatively impact the stability and lateral film organization of lung surfactant model systems. Nanomedicine, 2022, 17, 827-843.	3.3	9
6	Compounded Nonsterile Preparations and FDA-Approved Commercially Available Liquid Products for Children: A North American Update. Pharmaceutics, 2022, 14, 1032.	4.5	4
7	Antibiotic-loaded lipid-based nanocarrier: A promising strategy to overcome bacterial infection. International Journal of Pharmaceutics, 2022, 621, 121782.	5.2	14
8	Using GastroPlus to teach complex biopharmaceutical concepts. Pharmacy Education, 2022, 22, 336-347.	0.6	2
9	Interaction of M2 macrophages with hepatocellular carcinoma co-culture system in the presence of doxorubicin-loaded nanoparticles. Journal of Drug Delivery Science and Technology, 2022, , 103487.	3.0	0
10	Biomedical Applications of polymeric micelles in the treatment of diabetes mellitus: Current success and future approaches. Expert Opinion on Drug Delivery, 2022, 19, 771-793.	5.0	4
11	Special focus issue on targeted drug delivery for inflammatory lung diseases. Nanomedicine, 2022, 17, 813-815.	3.3	2
12	Enhanced In Vitro Antimicrobial Activity of Polymyxin Bâ€“Coated Nanostructured Lipid Carrier Containing Dexamethasone Acetate. Journal of Pharmaceutical Innovation, 2021, 16, 125-135.	2.4	13
13	Anti-inflammatory drug nanocrystals: state of art and regulatory perspective. European Journal of Pharmaceutical Sciences, 2021, 158, 105654.	4.0	21
14	Are the release characteristics of Erzhi pills in line with traditional Chinese medicine theory? A quantitative study. Journal of Integrative Medicine, 2021, 19, 50-55.	3.1	9
15	Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics. Journal of Microencapsulation, 2021, 38, 192-202.	2.8	7
16	Traditional Chinese Medicine â€œPillâ€ an Ancient Dosage Form with Surprising Modern Pharmaceutical Characteristics. Pharmaceutical Research, 2021, 38, 199-211.	3.5	7
17	Drug delivery advances in mitigating inflammation via matrix metalloproteinases in respiratory diseases. Nanomedicine, 2021, 16, 437-439.	3.3	5
18	Applications and practice of advanced drug delivery systems for targeting Toll-like receptors in pulmonary diseases. Nanomedicine, 2021, 16, 783-786.	3.3	7

#	Article	IF	Citations
19	Advanced drug delivery systems targeting NF-Î¹B in respiratory diseases. Future Medicinal Chemistry, 2021, 13, 1087-1090.	2.3	7
20	Development of a novel cannabinoid-loaded microemulsion towards an improved stability and transdermal delivery. International Journal of Pharmaceutics, 2021, 604, 120766.	5.2	21
21	Physiologically relevant dissolution conditions towards improved in vitro - in vivo relationship â€“ A case study with enteric coated pantoprazole tablets. International Journal of Pharmaceutics, 2021, 605, 120857.	5.2	3
22	Revolutionizing polymer-based nanoparticle-linked vaccines for targeting respiratory viruses: A perspective. Life Sciences, 2021, 280, 119744.	4.3	11
23	Oral delivery of solid lipid nanoparticles: underlining the physicochemical characteristics and physiological condition affecting the lipolysis rate. Expert Opinion on Drug Delivery, 2021, 18, 1707-1722.	5.0	8
24	Rational design of oral flubendazole-loaded nanoemulsion for brain delivery in cryptococcosis. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2021, 630, 127631.	4.7	11
25	The Lymphatic System: A Sometimes-Forgotten Compartment in Pharmaceutical Sciences. Journal of Pharmacy and Pharmaceutical Sciences, 2021, 24, 533-547.	2.1	7
26	Effects of self-assembled cell-penetrating peptides and their nano-complexes on ABCB1 expression and activity. Iranian Journal of Basic Medical Sciences, 2021, 24, 383-390.	1.0	0
27	A BCS-Based Biowaiver Approach Using Biphasic Dissolution Test. Dissolution Technologies, 2021, 28, 40-48.	0.6	0
28	Advances in ophthalmic preparation: the role of drug nanocrystals and lipid-based nanosystems. Journal of Drug Targeting, 2020, 28, 259-270.	4.4	23
29	Design space approach in the development of esculetin nanocrystals by a small-scale wet-bead milling process. Journal of Drug Delivery Science and Technology, 2020, 55, 101486.	3.0	13
30	Enhancement of the intestinal absorption of bortezomib by self-nanoemulsifying drug delivery system. Pharmaceutical Development and Technology, 2020, 25, 351-358.	2.4	11
31	Cutting-edge advances in therapy for the posterior segment of the eye: Solid lipid nanoparticles and nanostructured lipid carriers. International Journal of Pharmaceutics, 2020, 589, 119831.	5.2	29
32	Cancer treatment in the lymphatic system: A prospective targeting employing nanostructured systems. International Journal of Pharmaceutics, 2020, 587, 119697.	5.2	7
33	N,N,N-trimethylchitosan-poly (n-butylcyanoacrylate) core-shell nanoparticles as a potential oral delivery system for acyclovir. Colloids and Surfaces B: Biointerfaces, 2020, 196, 111336.	5.0	3
34	Cationic rifampicin nanoemulsion for the treatment of ocular tuberculosis. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2020, 597, 124755.	4.7	31
35	Biphasic Dissolution as an Exploratory Method during Early Drug Product Development. Pharmaceutics, 2020, 12, 420.	4.5	8
36	Importance of the fatty acid chain length on in vitro and in vivo anticancer activity of fattigation-platform albumin nanoparticles in human colorectal cancer xenograft mice model. Journal of Controlled Release, 2020, 324, 55-68.	9.9	12

#	Article	IF	Citations
37	Rifampicin nanocrystals: Towards an innovative approach to treat tuberculosis. Materials Science and Engineering C, 2020, 112, 110895.	7.3	12
38	Raman Spectroscopy for Quantitative Analysis in the Pharmaceutical Industry. Journal of Pharmacy and Pharmaceutical Sciences, 2020, 23, 24-46.	2.1	17
39	Phytocannabinoid drug-drug interactions and their clinical implications. , 2020, 215, 107621.		15
40	Mechanistic understanding of underperforming enteric coated products: Opportunities to add clinical relevance to the dissolution test. Journal of Controlled Release, 2020, 325, 323-334.	9.9	10
41	Fatty acid chain length impacts nanonizing capacity of albumin-fatty acid nanomicelles: Enhanced physicochemical property and cellular delivery of poorly water-soluble drug. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 152, 257-269.	4.3	15
42	A new medium-throughput screening design approach for the development of hydroxymethylnitrofurazone (NFOH) nanostructured lipid carrier for treating leishmaniasis. Colloids and Surfaces B: Biointerfaces, 2020, 193, 111097.	5.0	9
43	In silico Tools at Early Stage of Pharmaceutical Development: Data Needs and Software Capabilities. AAPS PharmSciTech, 2019, 20, 243.	3.3	5
44	Co-delivery of buparvaquone and polymyxin B in a nanostructured lipid carrier for leishmaniasis treatment. Journal of Global Antimicrobial Resistance, 2019, 18, 279-283.	2.2	14
45	LCâ€“MS/MS quantitation of phytocannabinoids and their metabolites in biological matrices. Talanta, 2019, 204, 846-867.	5.5	29
46	â€œDevelopment of Fixed Dose Combination Productsâ€•Workshop Report: Considerations of Gastrointestinal Physiology and Overall Development Strategy. AAPS Journal, 2019, 21, 75.	4.4	7
47	Simulated, biorelevant, clinically relevant or physiologically relevant dissolution media: The hidden role of bicarbonate buffer. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 142, 8-19.	4.3	34
48	Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 141, 58-69.	4.3	63
49	In Silico Prediction of Plasma Concentrations of Fluconazole Capsules with Different Dissolution Profiles and Bioequivalence Study Using Population Simulation. Pharmaceutics, 2019, 11, 215.	4.5	15
50	Highly Water-Soluble Orotic Acid Nanocrystals Produced by High-Energy Milling. Journal of Pharmaceutical Sciences, 2019, 108, 1848-1856.	3.3	14
51	The Irrelevance of InÂVitro Dissolution in Setting Product Specifications for Drugs Like Dextromethorphan That are Subject to Lysosomal Trapping. Journal of Pharmaceutical Sciences, 2019, 108, 268-278.	3.3	20
52	Olive oil nanoemulsion preparation using high-pressure homogenization and d-phase emulsification â€“ A design space approach. Journal of Drug Delivery Science and Technology, 2019, 49, 622-631.	3.0	35
53	Orally disintegrating dosage forms. Journal of Pharmaceutical Investigation, 2019, 49, 229-243.	5.3	25
54	Measuring the Impact of Gastrointestinal Variables on the Systemic Outcome of Two Suspensions of Posaconazole by a PBPK Model. AAPS Journal, 2018, 20, 57.	4.4	19

#	Article	IF	Citations
55	Synergistic photoprotective activity of nanocarrier containing oil of Acrocomia aculeata (Jacq.) Lodd. Ex. Martiusâ€"Arecaceae. Industrial Crops and Products, 2018, 112, 305-312.	5.2	24
56	Evaluation of a microemulsion-based gel formulation for topical drug delivery of diclofenac sodium. Journal of Pharmaceutical Investigation, 2018, 48, 351-362.	5.3	50
57	Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells. Acta Biomaterialia, 2018, 66, 294-309.	8.3	31
58	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humansâ€"Part 2: Fed State. Molecular Pharmaceutics, 2018, 15, 5468-5478.	4.6	12
59	Nano-sized Droplets of Self-Emulsifying System for Enhancing Oral Bioavailability of Chemotherapeutic Agent VP-16 in Rats: A Nano Lipid Carrier for BCS Class IV Drugs. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 398-408.	2.1	17
60	Application of in Silico Tools in Clinical Practice using Ketoconazole as a Model Drug. Journal of Pharmacy and Pharmaceutical Sciences, 2018, 21, 242s-253s.	2.1	7
61	Linking the Gastrointestinal Behavior of Ibuprofen with the Systemic Exposure between and within Humansâ€"Part 1: Fasted State Conditions. Molecular Pharmaceutics, 2018, 15, 5454-5467.	4.6	21
62	Additive Polyplexes to Undertake siRNA Therapy against CDC20 and Survivin in Breast Cancer Cells. Biomacromolecules, 2018, 19, 4193-4206.	5.4	23
63	Gastric emptying and intestinal appearance of nonabsorbable drugs phenol red and paromomycin in human subjects: A multi-compartment stomach approach. European Journal of Pharmaceutics and Biopharmaceutics, 2018, 129, 162-174.	4.3	24
64	High internal vegetable oil nanoemulsion: D-phase emulsification as a unique low energy process. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2018, 554, 296-305.	4.7	27
65	Promising nanotherapy in treating leishmaniasis. International Journal of Pharmaceutics, 2018, 547, 421-431.	5.2	59
66	The Significance of Disintegration Testing in Pharmaceutical Development. Dissolution Technologies, 2018, 25, 30-38.	0.6	24
67	In Silico Simulation of Dissolution Profiles for Development of Extended-Release Doxazosin Tablets. Dissolution Technologies, 2018, 25, 14-21.	0.6	5
68	Biowaiver Monographs for Immediate-Release Solid Oral Dosage Forms: Enalapril. Journal of Pharmaceutical Sciences, 2017, 106, 1933-1943.	3.3	27
69	Targeting Leishmania amazonensis amastigotes through macrophage internalisation of a hydroxymethylnitrofurazone nanostructured polymeric system. International Journal of Antimicrobial Agents, 2017, 50, 88-92.	2.5	21
70	Evolution of Choice of Solubility and Dissolution Media After Two Decades of Biopharmaceutical Classification System. AAPS Journal, 2017, 19, 989-1001.	4.4	69
71	Mechanistic understanding of the effect of renal impairment on metformin oral absorption using computer simulations. Journal of Pharmaceutical Investigation, 2017, 47, 151-161.	5.3	8
72	Erding Formula in hyperuricaemia treatment: unfolding traditional Chinese herbal compatibility using modern pharmaceutical approaches. Journal of Pharmacy and Pharmacology, 2017, 70, 124-132.	2.4	8

#	Article	IF	Citations
73	Pharmacokinetic and Toxicodynamic Characterization of a Novel Doxorubicin Derivative. Pharmaceutics, 2017, 9, 35.	4.5	26
74	Buparvaquone Nanostructured Lipid Carrier: Development of an Affordable Delivery System for the Treatment of Leishmaniases. BioMed Research International, 2017, 2017, 1-11.	1.9	29
75	Justification of disintegration testing beyond current FDA criteria using in vitro and in silico models. Drug Design, Development and Therapy, 2017, Volume11, 1163-1174.	4.3	23
76	Evaluation of the Rupture Test for Stability Studies of Soft-Shell Capsules. Dissolution Technologies, 2017, 24, 16-19.	0.6	5
77	Intrinsic dissolution simulation of highly and poorly soluble drugs for BCS solubility classification. Dissolution Technologies, 2017, 24, 6-11.	0.6	6
78	Challenges and Future Prospects of Nanoemulsion as a Drug Delivery System. Current Pharmaceutical Design, 2017, 23, 495-508.	1.9	76
79	Crystal-liquid Fugacity Ratio as a Surrogate Parameter for Intestinal Permeability. Journal of Pharmacy and Pharmaceutical Sciences, 2016, 19, 312.	2.1	2
80	Development of an algorithm to identify mass production candidate molecules to develop childrenâ€™s oral medicines: a North American perspective. AAPS Open, 2016, 2, .	1.3	3
81	Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells. Journal of Biomedical Materials Research - Part A, 2016, 104, 3031-3044.	4.0	20
82	Fabrication andin vitrocharacterization of gadolinium-based nanoclusters for simultaneous drug delivery and radiation enhancement. Nanotechnology, 2016, 27, 385104.	2.6	6
83	Inflammation Caused by Nanosized Delivery Systems: Is There a Benefit?. Molecular Pharmaceutics, 2016, 13, 3270-3278.	4.6	7
84	Immune response to antituberculosis drug-loaded gelatin and polyisobutyl-cyanoacrylate nanoparticles in macrophages. Therapeutic Delivery, 2016, 7, 213-228.	2.2	9
85	Disease specific modeling: Simulation of the pharmacokinetics of meloxicam and ibuprofen in disease state vs. healthy conditions. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 100, 77-84.	4.3	26
86	Physicalâ€“chemical properties of furosemide nanocrystals developed using rotation revolution mixer. Pharmaceutical Development and Technology, 2016, 21, 812-822.	2.4	8
87	Brush border membrane vesicle and Caco-2 cell line: Two experimental models for evaluation of absorption enhancing effects of saponins, bile salts, and some synthetic surfactants. Journal of Advanced Pharmaceutical Technology and Research, 2016, 7, 75.	1.0	11
88	Traditional Chinese Medicine for Managing Inflammatory Pain of Arthritis with Herbal Medicines. Current Traditional Medicine, 2016, 2, 80-93.	0.4	1
89	Design Space Approach for Preservative System Optimization of an Anti-Aging Eye Fluid Emulsion. Journal of Pharmacy and Pharmaceutical Sciences, 2015, 18, 551.	2.1	13
90	An Algorithm to Identify Compounded Non-Sterile Products that Can Be Formulated on a Commercial Scale or Imported to Promote Safer Medication Use in Children. Pharmacy (Basel, Switzerland), 2015, 3, 284-294.	1.6	6

#	Article	IF	Citations
91	Physicochemical, in vitro and in vivo evaluation of flurbiprofen microemulsion. Anais Da Academia Brasileira De Ciencias, 2015, 87, 1823-1831.	0.8	23
92	Reverse phase high-performance liquid chromatography for quantification of hydroxymethylnitrofurazone in polymeric nanoparticles. Brazilian Journal of Pharmaceutical Sciences, 2015, 51, 561-567.	1.2	5
93	The critical role of NIR spectroscopy and statistical process control (SPC) strategy towards captopril tablets (25â€‰mg) manufacturing process understanding: a case study. Pharmaceutical Development and Technology, 2015, 20, 345-351.	2.4	5
94	Transdermal drug delivery: feasibility for treatment of superficial bone stress fractures. Drug Delivery and Translational Research, 2015, 5, 540-551.	5.8	4
95	Hyaluronic Acid-Tocopherol Succinate-Based Self-Assembling Micelles for Targeted Delivery of Rifampicin to Alveolar Macrophages. Journal of Biomedical Nanotechnology, 2015, 11, 1312-1329.	1.1	34
96	Simulation of In Vitro Dissolution Behavior Using DDDPlusâ„¢. AAPS PharmSciTech, 2015, 16, 217-221.	3.3	22
97	Comparing the Dissolution Profiles of Seven Metformin Formulations in Simulated Intestinal Fluid. Dissolution Technologies, 2015, 22, 17-21.	0.6	7
98	What Western Pharmacists Need to Know About Traditional Chinese Medicine; A Canadian Perspective. Current Traditional Medicine, 2015, 1, 18-25.	0.4	1
99	Liposomal Drug Delivery: A Versatile Platform for Challenging Clinical Applications. Journal of Pharmacy and Pharmaceutical Sciences, 2014, 17, 401.	2.1	120
100	Evaluation of the DDSolver Software Applications. BioMed Research International, 2014, 2014, 1-9.	1.9	69
101	Antiulcerogenic Potential Activity of Free and NanoencapsulatedPassiflora serratodigitataL. Extracts. BioMed Research International, 2014, 2014, 1-7.	1.9	15
102	Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly(d,l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids and Surfaces B: Biointerfaces, 2014, 118, 154-163.	5.0	145
103	Investigating the Dissolution Profiles of Amoxicillin, Metronidazole, and Zidovudine Formulations used in Trinidad and Tobago, West Indies. AAPS PharmSciTech, 2014, 15, 1060-1069.	3.3	7
104	Challenges and Opportunities to Use Biowaivers to Compare Generics in China. AAPS PharmSciTech, 2014, 15, 1070-1075.	3.3	5
105	In Vitro Dissolution of Generic Immediate-Release Solid Oral Dosage Forms Containing BCS Class I Drugs: Comparative Assessment of Metronidazole, Zidovudine, and Amoxicillin Versus Relevant Comparator Pharmaceutical Products in South Africa and India. AAPS PharmSciTech, 2014, 15, 1076-1086.	3.3	20
106	Development of an ultrasensitive hetero-sandwich ELISA assay based on bispecific monoclonal antibody for the detection of dengue NS1 protein. Journal of Pharmacy Research, 2013, 7, 374-380.	0.4	3
107	Establishing the Pharmaceutical Quality of Chinese Herbal Medicine: A Provisional BCS Classification. Molecular Pharmaceutics, 2013, 10, 1623-1643.	4.6	41
108	In VitroRelease Kinetics of Antituberculosis Drugs from Nanoparticles Assessed Using a Modified Dissolution Apparatus. BioMed Research International, 2013, 2013, 1-9.	1.9	54

#	Article	IF	Citations
109	Investigation of the Disintegration Behavior of Dietary Supplements in Different Beverages. Dissolution Technologies, 2013, 20, 6-9.	0.6	11
110	Toward Global Standards for Comparator Pharmaceutical Products: Case Studies of Amoxicillin, Metronidazole, and Zidovudine in the Americas. AAPS Journal, 2012, 14, 462-472.	4.4	23
111	In-Vitro and In-Vivo Binding Activity of Chicken Egg Yolk Immunoglobulin Y (IgY) against Gliadin in Food Matrix. Journal of Agricultural and Food Chemistry, 2012, 60, 3166-3172.	5.2	35
112	Distribution of effervescent inhalable nanoparticles after pulmonary delivery: an in vivo study. Therapeutic Delivery, 2012, 3, 725-734.	2.2	24
113	Provisional Biopharmaceutical Classification of Some Common Herbs Used in Western Medicine. Molecular Pharmaceutics, 2012, 9, 815-822.	4.6	44
114	Production and characterization of antibodies against crosslinked gelatin nanoparticles and first steps toward developing an ELISA screening kit. Analytical and Bioanalytical Chemistry, 2012, 403, 2851-2857.	3.7	15
115	Pulmonary delivery of inhalable nanoparticles: dry powder inhalers. Therapeutic Delivery, 2011, 2, 1313-1324.	2.2	44
116	Inhalable nanoparticles, a non-invasive approach to treat lung cancer in a mouse model. Journal of Controlled Release, 2011, 150, 49-55.	9.9	154
117	Microcalorimetric Method to Assess Phagocytosis: Macrophage-Nanoparticle Interactions. AAPS Journal, 2011, 13, 20-29.	4.4	6
118	Pulmonary Toxicity of Polysorbate-80-coated Inhalable Nanoparticles; In vitro and In vivo Evaluation. AAPS Journal, 2010, 12, 294-299.	4.4	27
119	Isothermal Microcalorimetry as a Quality by Design Tool to Determine Optimal Blending Sequences. AAPS Journal, 2010, 12, 417-423.	4.4	1
120	Investigation of the Performance of the Disintegration Test for Dietary Supplements. AAPS Journal, 2010, 12, 602-607.	4.4	15
121	Secondary cytotoxicity mediated by alveolar macrophages: A contribution to the total efficacy of nanoparticles in lung cancer therapy?. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 112-119.	4.3	37
122	Real-Time Imaging of Interactions Between Dipalmitoylphosphatidylcholine Monolayers and Gelatin Based Nanoparticles Using Brewster Angle Microscopy. Journal of Biomedical Nanotechnology, 2010, 6, 145-152.	1.1	15
123	Influence of the Changed USP Specifications on Disintegration Test Performance. Dissolution Technologies, 2010, 17, 6-10.	0.6	9
124	Computer simulations using GastroPlusâ„¢ to justify a biowaiver for etoricoxib solid oral drug products. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 72, 91-98.	4.3	104
125	Dynamic Dissolution Testing To Establish In Vitro/In Vivo Correlations for Montelukast Sodium, a Poorly Soluble Drug. Pharmaceutical Research, 2008, 25, 2778-2785.	3.5	100
126	The effect of compression forces on the stability of dibasic calcium phosphate dihydrate tablets in the presence of glutamic acid hydrochloride monitored by isothermal calorimetry. Thermochimica Acta, 2008, 467, 86-90.	2.7	3

#	Article	IF	Citations
127	Targeted delivery of nanoparticles for the treatment of lung diseases. Advanced Drug Delivery Reviews, 2008, 60, 863-875.	13.7	375
128	Formulation and In Vivo Evaluation of Effervescent Inhalable Carrier Particles for Pulmonary Delivery of Nanoparticles. Drug Development and Industrial Pharmacy, 2008, 34, 943-947.	2.0	31
129	Physicochemical characterization of five glyburide powders: A BCS based approach to predict oral absorption. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 69, 1046-1056.	4.3	47
130	Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans. European Journal of Pharmaceutics and Biopharmaceutics, 2008, 70, 313-325.	4.3	46
131	Size Dependent Interactions of Nanoparticles with Lung Surfactant Model Systems and the Significant Impact on Surface Potential. Journal of Nanoscience and Nanotechnology, 2008, 8, 2971-2978.	0.9	23
132	Nanoparticles: Characteristics, Mechanisms of Action, and Toxicity in Pulmonary Drug Deliveryâ€"A Review. Journal of Biomedical Nanotechnology, 2007, 3, 107-119.	1.1	99
133	Effervescent dry powder for respiratory drug delivery. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 65, 346-353.	4.3	70
134	Current perspectives in dissolution testing of conventional and novel dosage forms. International Journal of Pharmaceutics, 2007, 328, 12-21.	5.2	218
135	A mini review of scientific and pharmacopeial requirements for the disintegration test. International Journal of Pharmaceutics, 2007, 345, 2-8.	5.2	41
136	Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle. AAPS PharmSciTech, 2007, 8, E78-E87.	3.3	19
137	A Method for the Analysis of Ginsenosides, Malonyl Ginsenosides, and Hydrolyzed Ginsenosides Using High-Performance Liquid Chromatography with Ultraviolet and PositiveMode Electrospray IonizationMass Spectrometric Detection. Journal of AOAC INTERNATIONAL, 2006, 89, 16-21.	1.5	14
138	Formulation and cytotoxicity of doxorubicin nanoparticles carried by dry powder aerosol particles. International Journal of Pharmaceutics, 2006, 319, 155-161.	5.2	136
139	Biorelevant dissolution media as a predictive tool for glyburide a class II drug. European Journal of Pharmaceutical Sciences, 2006, 29, 45-52.	4.0	125
140	Activation of a photosensitive pharmaceutical agent by a triboluminescent material. Applied Physics Letters, 2006, 88, 123901.	3.3	4
141	Biophysical Investigation of Nanoparticle Interactions with Lung Surfactant Model Systems. Journal of Biomedical Nanotechnology, 2006, 2, 245-252.	1.1	26
142	Investigation of vitamin and mineral tablets and capsules on the Canadian market. Journal of Pharmacy and Pharmaceutical Sciences, 2006, 9, 40-9.	2.1	5
143	Optimization of a two-step desolvation method for preparing gelatin nanoparticles and cell uptake studies in 143B osteosarcoma cancer cells. Journal of Pharmacy and Pharmaceutical Sciences, 2006, 9, 124-32.	2.1	92
144	Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. European Journal of Pharmaceutics and Biopharmaceutics, 2005, 60, 17-23.	4.3	28

#	Article	IF	Citations
145	Mechanistic evaluation of the effect of thermal-treating on Eudragit RS matrices. Il Farmaco, 2005, 60, 925-930.	0.9	24
146	Imparting bone mineral affinity to osteogenic proteins through heparinâ€“bisphosphonate conjugates. Journal of Controlled Release, 2004, 98, 255-268.	9.9	26
147	Impact of Tether Length on Bone Mineral Affinity of Protein-Bisphosphonate Conjugates. Pharmaceutical Research, 2004, 21, 608-616.	3.5	20
148	Formulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lung. International Journal of Pharmaceutics, 2004, 269, 457-467.	5.2	245
149	Physicochemical Characterization of Solid Dispersions of Indomethacin with PEG 6000, Myrj 52, Lactose, Sorbitol, Dextrin, and EudragitÂ® E100. Drug Development and Industrial Pharmacy, 2004, 30, 303-317.	2.0	115
150	Interaction of Poly(butylcyanoacrylate) Nanoparticles with the Blood-Brain Barrierin vivoandin vitro. Journal of Drug Targeting, 2001, 9, 209-221.	4.4	163
151	Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharmaceutical Research, 2000, 17, 439-444.	3.5	92
152	Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. European Journal of Pharmaceutics and Biopharmaceutics, 2000, 50, 3-12.	4.3	588
153	Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of the body distribution after suspension in surfactant solutions and in oil vehicles. International Journal of Pharmaceutics, 1999, 176, 209-224.	5.2	71
154	Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharmaceutical Research, 1998, 15, 698-705.	3.5	796
155	Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. Journal of Controlled Release, 1998, 50, 21-30.	9.9	98
156	Body distribution of azidothymidine bound to nanoparticles after oral administration. European Journal of Pharmaceutics and Biopharmaceutics, 1997, 44, 127-132.	4.3	63
157	Macrophage Targeting of Azidothymidine: A Promising Strategy for AIDS Therapy*. AIDS Research and Human Retroviruses, 1996, 12, 1709-1715.	1.1	61
158	Esculetin as bioactive marker: towards a rational scientific approach for the treatment of hyperuricemia using Traditional Chinese Medicine. Brazilian Journal of Pharmaceutical Sciences, 0, 56, .	1.2	3